Nashville, Tennessee 37232


Purpose:

The investigators will test the hypothesis that acute central acetylcholinesterase inhibition will restore PNS activity and reduce oxidation in AAW compared to whites.


Study summary:

Obesity has a greater detrimental impact on the health of African American women (AAW) than on any other racial or gender group. Nearly 80% of AAW are overweight or obese. Reduced insulin sensitivity is more prevalent among AAW as compared to white women and men of both races. This condition puts AAW at increased risk for the development of type 2 diabetes mellitus. The exact mechanism underlying these pathophysiological differences remains unknown. The investigators have found that obese AAW have decreased parasympathetic nerve (PNS) activity compared to whites and recent studies in animal models showed that the PNS confers protection against oxidative stress. In our AA cohort, PNS activity was directly correlated with insulin sensitivity in obese AAW even after controlling for differences in age, blood pressure and visceral adiposity. Equally important, the investigators also showed that the decrease in insulin sensitivity was associated with increased oxidative stress as measured by plasma levels of F2-isoprostanes. Taken together these findings lead us to hypothesize that the decreased PNS activity in obese AAW compared to white women has deleterious effects on oxidative stress and insulin sensitivity.The investigators will test the hypothesis that acute central acetylcholinesterase inhibition will restore PNS activity and reduce oxidation in AAW compared to whites.


Criteria:

Inclusion Criteria: - Female - African American or white (race will be self-defined, but only subjects who report both parents of the same race will be included) - 18-60 years old - BMI 30-45 Kg/m2 - Not pregnant or breastfeeding Exclusion Criteria: - Pregnant or breastfeeding - Diabetes diagnosis (defined by the American Diabetes Association (ADA) criteria)38 - Cardiovascular disease such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy. - Arrhythmia (first-, second-, and third-degree atrioventricular (AV) block) - Significant weight change >5% in the past 3 months - Impaired hepatic function (AST and/or Alanine transaminase (ALT) > one and one half times (1.5X) upper limit of normal range) - Impaired renal function (eGFR <60ml/min) - Users of strong inhibitors of Cytochrome P450 3A4 (CYP3A4) or cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) - Users of other acetylcholinesterase inhibitors such as pyridostigmine or bethanechol - History of alcohol or drug abuse - Mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study - Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study


NCT ID:

NCT02365285


Primary Contact:

Principal Investigator
Cyndya Shibao, MD
Vanderbilt University Medical Center, Clinical Pharmacology

Keisha Card, RN
Email: keisha.card@vanderbilt.edu


Backup Contact:

Email: cyndya.shibao@vanderbilt.edu
Cyndya Shibao, MD


Location Contact:

Nashville, Tennessee 37232
United States

Cyndya Shibao, MD
Email: cyndya.shibao@vanderbilt.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.